Crystal Nucleus Biomedical Technology

Crystal Nucleus is a clinical-stage biotechnology company specializing in the development of next-generation targeted radiopharmaceuticals, with a core focus on Targeted Alpha Therapy (TAT). The company utilizes its proprietary platform to engineer ligands conjugated with alpha-emitting isotopes, such as Actinium-225, to provide highly localized and potent treatment for various cancers. Its lead program, JH02, is a PSMA-targeted radioligand therapy currently in clinical development for prostate cancer. Headquartered in Suzhou, China, Crystal Nucleus aims to establish a leading position in the global radiopharmaceutical market through innovative drug design and robust manufacturing capabilities. The company's pipeline also includes candidates targeting Fibroblast Activation Protein (FAP) and other undisclosed oncology markers. Crystal Nucleus has successfully raised significant capital from prominent investors like GL Ventures and Gaorong Capital to accelerate its clinical and preclinical programs.